SK8552002A3 - EP4 receptor selective agonists in the treatment of osteoporosis - Google Patents

EP4 receptor selective agonists in the treatment of osteoporosis Download PDF

Info

Publication number
SK8552002A3
SK8552002A3 SK855-2002A SK8552002A SK8552002A3 SK 8552002 A3 SK8552002 A3 SK 8552002A3 SK 8552002 A SK8552002 A SK 8552002A SK 8552002 A3 SK8552002 A3 SK 8552002A3
Authority
SK
Slovakia
Prior art keywords
pyrrolidin
hydroxy
bone
butyl
heptanoic acid
Prior art date
Application number
SK855-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Kimberly O'keefe Cameron
Huazhu Ke
Bruce Allen Lefker
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SK8552002A3 publication Critical patent/SK8552002A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SK855-2002A 1999-12-22 2000-11-20 EP4 receptor selective agonists in the treatment of osteoporosis SK8552002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17135399P 1999-12-22 1999-12-22
PCT/IB2000/001711 WO2001046140A1 (en) 1999-12-22 2000-11-20 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
SK8552002A3 true SK8552002A3 (en) 2003-09-11

Family

ID=22623430

Family Applications (1)

Application Number Title Priority Date Filing Date
SK855-2002A SK8552002A3 (en) 1999-12-22 2000-11-20 EP4 receptor selective agonists in the treatment of osteoporosis

Country Status (36)

Country Link
US (2) US6737437B2 (cs)
EP (1) EP1110949B1 (cs)
JP (1) JP2001181210A (cs)
KR (1) KR100419681B1 (cs)
CN (1) CN1413190A (cs)
AP (2) AP2002002555A0 (cs)
AT (1) ATE250575T1 (cs)
AU (2) AU1293101A (cs)
BG (1) BG106882A (cs)
BR (1) BR0016560A (cs)
CA (1) CA2329678A1 (cs)
CO (1) CO5251453A1 (cs)
CR (1) CR6678A (cs)
CZ (1) CZ20022048A3 (cs)
DE (1) DE60005471T2 (cs)
DK (1) DK1110949T3 (cs)
EA (1) EA005293B1 (cs)
EE (1) EE200200355A (cs)
ES (1) ES2204458T3 (cs)
GE (1) GEP20043203B (cs)
HR (1) HRP20020537A2 (cs)
HU (1) HUP0005001A3 (cs)
IL (1) IL140325A0 (cs)
IS (1) IS6388A (cs)
MA (1) MA26852A1 (cs)
MX (1) MXPA02006322A (cs)
NO (1) NO20022925L (cs)
OA (1) OA12117A (cs)
PE (1) PE20010953A1 (cs)
PL (1) PL356662A1 (cs)
PT (1) PT1110949E (cs)
SK (1) SK8552002A3 (cs)
TR (2) TR200201643T2 (cs)
UA (1) UA72293C2 (cs)
WO (1) WO2001046140A1 (cs)
ZA (1) ZA200007694B (cs)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
EP1339678B1 (en) * 2000-11-27 2007-09-26 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
CN100371322C (zh) 2001-07-16 2008-02-27 霍夫曼-拉罗奇有限公司 作为前列腺素类化合物激动剂的2-吡咯烷酮衍生物
PL368046A1 (en) 2001-07-16 2005-03-21 F.Hoffmann-La Roche Ag Prostaglandin analogues_as ep4 receptor agonists
ES2360604T3 (es) * 2001-07-23 2011-06-07 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4.
WO2003009872A1 (en) * 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US20040258730A1 (en) * 2001-11-12 2004-12-23 Yasuhiko Tabata Persistent filmy preparation for topical administration containing prostglandin derivative
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
AU2002346561B2 (en) * 2001-12-03 2006-08-17 Merck & Co., Inc. EP4 receptor agonist, compositions and methods thereof
US7335680B2 (en) 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
CN1653046A (zh) 2002-03-05 2005-08-10 小野药品工业株式会社 8-氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物
BR0308493A (pt) * 2002-03-18 2005-01-11 Pfizer Prod Inc Uso de agonistas de receptor seletivo de ep4 para o tratamento da insuficiência hepática, perda de permeabilidade do canal arterial, glaucoma ou hipertensão ocular
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) * 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
US20050239872A1 (en) 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
PT1563846E (pt) 2002-10-10 2012-11-13 Ono Pharmaceutical Co Promotores da produção de factores endógenos de reparação
CA2505127A1 (en) 2002-11-08 2004-05-27 James B. Doherty Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
PL378342A1 (pl) * 2003-01-10 2006-03-20 F. Hoffmann-La Roche Ag Pochodne 2-piperydonu jako agoniści prostaglandyn
WO2004065365A1 (ja) * 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. 8−アザプロスタグランジン誘導体およびその医薬用途
US7276531B2 (en) 2003-03-03 2007-10-02 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
CA2529123A1 (en) * 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
CN1845914A (zh) 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
CN1842335A (zh) 2003-09-04 2006-10-04 默克公司 用于治疗高眼压的眼用组合物
WO2005026128A1 (en) 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
JP2008507521A (ja) 2004-07-20 2008-03-13 メルク エンド カムパニー インコーポレーテッド 高眼圧症を治療するための眼科用組成物
ES2336933T3 (es) 2004-12-06 2010-04-19 Merck Serono Sa Derivados de pirrolidin-2-ona para usar como antagonistas del receptor dp1.
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
WO2006118173A1 (ja) 2005-04-28 2006-11-09 Ono Pharmaceutical Co., Ltd. 経皮吸収製剤
KR100686186B1 (ko) * 2005-06-13 2007-02-26 영진종합건설 주식회사 교량용 배수 구조물
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
KR20090075864A (ko) 2006-10-26 2009-07-09 오노 야꾸힝 고교 가부시키가이샤 첨부제
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
EP2220057A4 (en) 2007-11-14 2011-10-12 Cayman Chem Co PROSTAGLANDIN E1 AND E2 ANALOGUES FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
WO2013018837A1 (ja) 2011-08-02 2013-02-07 小野薬品工業株式会社 左室拡張機能改善剤
EP3175852B1 (en) 2012-07-19 2019-03-06 Cayman Chemical Company, Incorporated Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
WO2014069401A1 (ja) 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
WO2014144584A2 (en) * 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス,インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
EP3307747A4 (en) 2015-06-12 2019-02-27 Simon Fraser University AMID LINKED EP4 AGONIST BISPHOSPHONATE COMPOUNDS AND USES THEREOF
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (fr) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Machine à rotors
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (cs) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US4055596A (en) 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
DE2528664A1 (de) * 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA1214170A (fr) 1981-06-16 1986-11-18 Patrick Choay Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide
AU6427596A (en) * 1992-04-14 1996-10-31 Alfred Maximillian Stessl A boat hull
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
ATE390917T1 (de) * 1996-12-20 2008-04-15 Pfizer Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
WO2000021532A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation

Also Published As

Publication number Publication date
DK1110949T3 (da) 2003-11-24
US20010047105A1 (en) 2001-11-29
US20020040149A1 (en) 2002-04-04
OA12117A (en) 2006-05-04
HUP0005001A3 (en) 2002-01-28
HUP0005001A2 (hu) 2001-12-28
WO2001046140A1 (en) 2001-06-28
CR6678A (es) 2004-01-14
CZ20022048A3 (cs) 2004-03-17
IL140325A0 (en) 2002-02-10
EP1110949B1 (en) 2003-09-24
AU7239300A (en) 2001-06-28
TR200301841T4 (tr) 2004-01-21
BR0016560A (pt) 2002-09-10
GEP20043203B (en) 2004-03-25
CA2329678A1 (en) 2001-06-22
ATE250575T1 (de) 2003-10-15
DE60005471T2 (de) 2004-04-22
HRP20020537A2 (en) 2004-12-31
PL356662A1 (en) 2004-06-28
JP2001181210A (ja) 2001-07-03
EA005293B1 (ru) 2004-12-30
BG106882A (en) 2003-02-28
TR200201643T2 (tr) 2002-11-21
MA26852A1 (fr) 2004-12-20
DE60005471D1 (de) 2003-10-30
KR20010067415A (ko) 2001-07-12
US6642266B2 (en) 2003-11-04
IS6388A (is) 2002-05-17
EP1110949A1 (en) 2001-06-27
NO20022925D0 (no) 2002-06-18
MXPA02006322A (es) 2002-12-13
CO5251453A1 (es) 2003-02-28
HU0005001D0 (cs) 2001-02-28
ES2204458T3 (es) 2004-05-01
CN1413190A (zh) 2003-04-23
EA200200505A1 (ru) 2002-12-26
ZA200007694B (en) 2002-06-20
AU763983B2 (en) 2003-08-07
US6737437B2 (en) 2004-05-18
UA72293C2 (en) 2005-02-15
NO20022925L (no) 2002-06-18
PE20010953A1 (es) 2001-09-25
AP2002002555A0 (en) 2002-06-30
PT1110949E (pt) 2003-12-31
KR100419681B1 (ko) 2004-02-21
AU1293101A (en) 2001-07-03
EE200200355A (et) 2003-10-15
AP2001002357A0 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
SK8552002A3 (en) EP4 receptor selective agonists in the treatment of osteoporosis
ES2291361T3 (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
JPH11180926A (ja) 骨粗しょう症用化合物
KR100620772B1 (ko) 에스트로겐과 2-페닐-1-[4-(2-아미노에톡시)-벤질]-인돌을 포함하는 약제학적 조성물
BG64582B1 (bg) Фармацевтичен състав за комбинирана терапия на остеопороза и използване
HRP980356A2 (en) Prostaglandin agonists
CA2334257C (en) Treatment of osteoporosis with ep2/ep4 receptor selective agonists
JP2000143541A (ja) 哺乳動物における認知機能不全症の予防及び治療用組成物
CN101842356A (zh) (3-(((4-叔丁基苄基)-(吡啶-3-磺酰基)-氨基)-甲基)-苯氧基)-乙酸钠盐或其水合物的多晶型体及其制备方法
HK1051366A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
WO2009027803A2 (en) Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
HK1145171A (en) Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof and methods for making the same

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure